Did You Catch Axios' Recent Headlines About the Boulder Terror Attack? Who's Running...
CNN's Panel on Antisemitism Was a Total Trainwreck
Reporter Gave a Laughable Reason for Why We Can't Trust Polls Now
I'm Not So Sure Bill Clinton Is the Person to Lead Point on...
CBS News' Margaret Brennan Got Wrecked By Scott Bessent and Marty Makary Over...
Watch Scott Jennings Obliterate a Reporter Over Her 'Both Sides' Nonsense on Political...
Here's What You Should Know About Mohamad Soliman
Jewish Americans Can No Longer Afford to Be Unarmed
Sanctuary States, Sleeper Cells, and a Nation on the Brink
White House Shuts Down One of the 'Most Disgusting Lies' Being Spread About...
Hey You, Get Off My Crowd
Two People Rescued After Plane Crashes Off the Coast of Connecticut
Marco Rubio Has a Warning for 'All Terrorists'
This Transgender Athlete Shared This Flippant Response After Dominating a Women's Race
Republicans Could Make History on Gun Rights
Tipsheet

The FDA Just Approved This Surprising Standalone Treatment for Depression

AP Photo/Andrew Harnik, File

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray to be used alone in adults with major depressive disorder. 

Advertisement

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression. This is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.

According to CNBC, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing thoughts of suicide or harm. 

“We want to recognize that this is a medicine that treats a disease that [when] left untreated, depression is potentially fatal,” Bill Martin, J&J’s global therapeutic area head of neuroscience, said in an interview with the outlet.

Advertisement

Reportedly, about one-third of the estimated 21 million U.S. adults with major depression battle symptoms don’t respond to treatment.

“For the first time ever, we now have an option that gives patients freedom,” Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said. 

Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren’t improving their symptoms and are causing undesirable side effects.

The approval of Spravato was based on a phase four trial that showed that Spravato alone improved depressive symptoms beginning about 24 hours after treatment and lasting through at least one month. The drug first entered the US market in 2019.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement